In an in vivo model of triple-negative breast cancer, both PPP and linsitinib in combination with oxaliplatin increase macro-autophagy and ATP release by the dying tumor cells resulting in DC activation, recruitment of cytotoxic CD8+ T cells, and decrease of T-regs number at the tumor site (57). Here, CD8A is linked to triple-negative breast carcinoma.